Crossmark Global Holdings Inc. Buys 670 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Crossmark Global Holdings Inc. lifted its stake in shares of BeiGene, Ltd. (NASDAQ:BGNEGet Rating) by 26.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,172 shares of the company’s stock after purchasing an additional 670 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in BeiGene were worth $428,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in shares of BeiGene during the 3rd quarter worth about $61,000. Steward Partners Investment Advisory LLC bought a new position in shares of BeiGene during the 2nd quarter worth about $65,000. Whittier Trust Co. of Nevada Inc. bought a new position in shares of BeiGene during the 3rd quarter worth about $165,000. Advisors Asset Management Inc. boosted its position in shares of BeiGene by 26.7% during the 1st quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company’s stock worth $235,000 after purchasing an additional 262 shares in the last quarter. Finally, Desjardins Global Asset Management Inc. boosted its position in shares of BeiGene by 7.6% during the 2nd quarter. Desjardins Global Asset Management Inc. now owns 1,523 shares of the company’s stock worth $246,000 after purchasing an additional 107 shares in the last quarter. Institutional investors own 51.43% of the company’s stock.

BeiGene Trading Down 2.9 %

NASDAQ:BGNE opened at $266.42 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.87 and a current ratio of 4.07. The firm has a market cap of $27.70 billion, a price-to-earnings ratio of -12.48 and a beta of 0.78. BeiGene, Ltd. has a 52 week low of $118.18 and a 52 week high of $280.62. The firm has a 50-day moving average price of $217.59 and a two-hundred day moving average price of $185.80.

BeiGene (NASDAQ:BGNEGet Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($5.39) EPS for the quarter, missing the consensus estimate of ($4.02) by ($1.37). The firm had revenue of $387.63 million during the quarter, compared to analysts’ expectations of $360.25 million. BeiGene had a negative net margin of 171.94% and a negative return on equity of 38.92%. On average, equities analysts expect that BeiGene, Ltd. will post -18.27 earnings per share for the current fiscal year.

Insider Buying and Selling at BeiGene

In other BeiGene news, CEO John Oyler sold 25,000 shares of the stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $206.84, for a total value of $5,171,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO John Oyler sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $206.84, for a total transaction of $5,171,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Xiaodong Wang sold 1,987 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $210.14, for a total transaction of $417,548.18. Following the sale, the insider now owns 5,629,556 shares of the company’s stock, valued at approximately $1,182,994,897.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,033 shares of company stock worth $9,407,504. Insiders own 7.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Daiwa Capital Markets assumed coverage on shares of BeiGene in a research report on Wednesday, January 11th. They set a “buy” rating and a $308.00 price objective on the stock. Cowen raised their price target on shares of BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. Guggenheim raised their price target on shares of BeiGene from $290.00 to $350.00 and gave the company a “buy” rating in a research report on Friday. StockNews.com raised shares of BeiGene from a “sell” rating to a “hold” rating in a research report on Saturday, November 19th. Finally, SVB Leerink raised their price target on shares of BeiGene from $236.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $282.14.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Articles

Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNEGet Rating).

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.